PMID- 24827123
OWN - NLM
STAT- MEDLINE
DCOM- 20151116
LR  - 20220330
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 25
IP  - 8
DP  - 2014 Aug
TI  - ABVD (8 cycles) versus BEACOPP (4 escalated cycles >/= 4 baseline): final results 
      in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized 
      trial.
PG  - 1622-8
LID - 10.1093/annonc/mdu189 [doi]
AB  - BACKGROUND: Treatment with escalated BEACOPP achieved a superior time to 
      treatment failure over ABVD in patients with disseminated Hodgkin lymphoma. 
      However, recent clinical trials have failed to confirm BEACOPP overall survival 
      (OS) superiority over ABVD. In addition, the gain in low-risk patients is still a 
      matter of debate. PATIENTS AND METHODS: We randomly compared ABVD (8 cycles) with 
      BEACOPP (escalated 4 cycles >/= baseline 4 cycles) in low-risk patients with an 
      International Prognostic Score (IPS) of 0-2. The primary end point was event-free 
      survival (EFS). This parallel group, open-label phase 3 trial was registered 
      under #RECF0219 at French National Cancer Institute. RESULTS: One hundred and 
      fifty patients were randomized in this trial (ABVD 80, BEACOPP 70): 28 years was 
      the median age, 50% were male and IPS was 0-1 for 64%. Complete remission rate 
      was 85% for ABVD and 90% for BEACOPP. Progression or relapses were more frequent 
      in the ABVD patients than in the BEACOPP patients (17 versus 5 patients). With a 
      median follow-up period of 5.5 years, seven patients died: six in the ABVD arm 
      and one in the BEACOPP arm (HL 3 and 0, 2nd cancer 2 and 1, accident 1 and 0). 
      The EFS at 5 years was estimated at 62% for ABVD versus 77%, for BEACOPP [hazards 
      ratio (HR) = 0.6, P = 0.07]. The progression-free survival (PFS) at 5 years was 
      75% versus 93% (HR = 0.3, P = 0.007). The OS at 5 years was 92% versus 99% (HR = 
      0.18, P = 0.06). CONCLUSION: Fewer progressions/relapses were observed with 
      BEACOPP, demonstrating the high efficacy of the more intensive regimen, even in 
      low-risk patients. However, additional considerations, balancing 
      treatment-related toxicity and late morbidity due to salvage may help with 
      decision-making with regard to treatment with ABVD or BEACOPP.
CI  - (c) The Author 2014. Published by Oxford University Press on behalf of the European 
      Society for Medical Oncology. All rights reserved. For permissions, please email: 
      journals.permissions@oup.com.
FAU - Mounier, N
AU  - Mounier N
AD  - Department of Onco-Hematology, Archet Hospital, Nice mounier.n@chu-nice.fr.
FAU - Brice, P
AU  - Brice P
AD  - Department of Hematology, Saint-Louis Hospital, Paris.
FAU - Bologna, S
AU  - Bologna S
AD  - Department of Hematology, Nancy Hospital.
FAU - Briere, J
AU  - Briere J
AD  - Department of Hematology, Saint-Louis Hospital, Paris.
FAU - Gaillard, I
AU  - Gaillard I
AD  - Department of Hematology, Henri Mondor Hospital, Creteil.
FAU - Heczko, M
AU  - Heczko M
AD  - Department of Hematology, Besancon Hospital.
FAU - Gabarre, J
AU  - Gabarre J
AD  - Department of Hematology, la Pitie-Salpetriere Hospital, Paris.
FAU - Casasnovas, O
AU  - Casasnovas O
AD  - Department of Hematology, CHU de Dijon Hospital, Dijon.
FAU - Jaubert, J
AU  - Jaubert J
AD  - Department of Hematology, St Etienne Hospital, St Etienne.
FAU - Colin, P
AU  - Colin P
AD  - Department of Hematology, Courlancy Cancer Institute, Reims.
FAU - Delmer, A
AU  - Delmer A
AD  - Department of Hematology, Reims Hospital, Reims.
FAU - Devidas, A
AU  - Devidas A
AD  - Department of Hematology, Corbeil Hospital, Corbeil Essonnes.
FAU - Bachy, E
AU  - Bachy E
AD  - Department of Hematology, Lyon Sud Hospital, Pierre Benite.
FAU - Nicolas-Virelizier, E
AU  - Nicolas-Virelizier E
AD  - Department of Hematology, Leon Berard Cancer Center, Lyon.
FAU - Aoudjhane, A
AU  - Aoudjhane A
AD  - Department of Hematology, St Antoine Hospital, Paris.
FAU - Humbrecht, C
AU  - Humbrecht C
AD  - Department of Hematology, Colmar Hospital, Colmar, France.
FAU - Andre, M
AU  - Andre M
AD  - Department of Hematology, Mont Godine Hospital, Yvoire, Belgium.
FAU - Carde, P
AU  - Carde P
AD  - Department of Hematology, Gustave Roussy Institute, Villejuif, France.
CN  - Lymphoma Study Association (LYSA)
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140514
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 11056-06-7 (Bleomycin)
RN  - 35S93Y190K (Procarbazine)
RN  - 5J49Q6B70F (Vincristine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - ABVD protocol
RN  - BEACOPP protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bleomycin/therapeutic use
MH  - Cyclophosphamide/therapeutic use
MH  - Dacarbazine/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Doxorubicin/therapeutic use
MH  - Etoposide/therapeutic use
MH  - Female
MH  - Hodgkin Disease/*drug therapy/mortality/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prednisone/therapeutic use
MH  - Procarbazine/therapeutic use
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Vinblastine/therapeutic use
MH  - Vincristine/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Hodgkin lymphoma
OT  - intensive chemotherapy
OT  - phase 3 trial
OT  - prognostic factors
OT  - secondary malignancy
FIR - Divine, M
IR  - Divine M
FIR - Fenaux, P
IR  - Fenaux P
FIR - Coiffier, B
IR  - Coiffier B
FIR - Reman, O
IR  - Reman O
FIR - Aoudjhane, M
IR  - Aoudjhane M
FIR - Blaise, A M
IR  - Blaise AM
FIR - Bordessoule, D
IR  - Bordessoule D
FIR - Bosly, A
IR  - Bosly A
FIR - Morschhauser, F
IR  - Morschhauser F
FIR - Caillot, D
IR  - Caillot D
FIR - Gonzalez, H
IR  - Gonzalez H
FIR - Lederlin, P
IR  - Lederlin P
FIR - Bouabdallah, R
IR  - Bouabdallah R
FIR - Van Hoof, A
IR  - Van Hoof A
FIR - Boulat, O
IR  - Boulat O
FIR - Bauduer, F
IR  - Bauduer F
FIR - Tournilhac, O
IR  - Tournilhac O
FIR - Decaudin, D
IR  - Decaudin D
FIR - Sebban, C
IR  - Sebban C
FIR - Janvier, M
IR  - Janvier M
FIR - Kentos, A
IR  - Kentos A
FIR - Voillat, L
IR  - Voillat L
FIR - Fabbro, M
IR  - Fabbro M
FIR - Eisenmann, J C
IR  - Eisenmann JC
FIR - Martin, C
IR  - Martin C
FIR - Christian, B
IR  - Christian B
FIR - Ferrant, A
IR  - Ferrant A
FIR - Salanoubat, C
IR  - Salanoubat C
FIR - Varet, B
IR  - Varet B
FIR - Bouabdallah, K
IR  - Bouabdallah K
FIR - De Prijck, B
IR  - De Prijck B
FIR - Levaltier, X
IR  - Levaltier X
FIR - Castaigne, S
IR  - Castaigne S
FIR - Audhuy, B
IR  - Audhuy B
FIR - Frenkiel, N
IR  - Frenkiel N
FIR - Rose, C
IR  - Rose C
FIR - Fitoussi, O
IR  - Fitoussi O
FIR - Orfeuvre, H
IR  - Orfeuvre H
FIR - Pignon, J M
IR  - Pignon JM
EDAT- 2014/05/16 06:00
MHDA- 2015/11/17 06:00
CRDT- 2014/05/16 06:00
PHST- 2014/05/16 06:00 [entrez]
PHST- 2014/05/16 06:00 [pubmed]
PHST- 2015/11/17 06:00 [medline]
AID - S0923-7534(19)34825-2 [pii]
AID - 10.1093/annonc/mdu189 [doi]
PST - ppublish
SO  - Ann Oncol. 2014 Aug;25(8):1622-8. doi: 10.1093/annonc/mdu189. Epub 2014 May 14.